1/40
Looks like no tags are added yet.
inflammation
response to cellular/tissue injury to phospholipid bilayer, foreign substance, or immune stimulation
early/vascular phase of inflammation
vasodilation, increased permeability of vessels, increased local perfusion, movement of blood substances and fluid from plasma to the injured tissue; up to a week long
delayed/cellular phase of inflammation
accumulation of leukocytes in inflamed tissue, reduced blood flow due to congestion, tissue damage may occur, increased activity of neutrophils, monocytes, lymphocytes; C/S: redness, heat, swelling pain, loss of sensation; lasts hours-days after injury
signs of inflammation
pain, heat, redness, swelling, decreased function
NSAIDs
cyclooxygenase inhibitors
COX-1 enzyme
produces protective/good, "housekeeping" prostaglandins; = PGE2, promotes mucus GI production and inhibits gastric acid secretion; = PGE2 and PG12, vasodilation of renal blood cells promoting perfusion
COX-2 enzyme
produces inflammatory prostaglandins
aspirin
non-selective NSAID (class: salicylates), more COX-2 activity; oldest anti-inflammatory agent; used for analgesia, antipyretic, anti-inflammatory, decreased platelet aggregation (anticoagulant); glucuronyl transferase enzyme needed to metabolize salicylates
phenylbutazone/bute
non-selective NSAID (class: pyrazolone derivatives) for equine pain with musculoskeletal injuries; class: pyrazolone derivatives
carprofen
non-selective NSAID (class: propionic acid derivatives), more COX-2 activity than COX-1; antipyretic, analgesic, anti-inflammatory
ketoprofen/ketofen
non-selective NSAID (class: propionic acid derivatives) for equines; inhibits COX and lipooxygenase
naproxen/equiproxen
non-selective NSAID (class: propionic acid derivatives) for equines
deracoxib/deramaxx
selective COX-2 inhibitor (class: coxib); has anti-cancer effects (transitional cell carcinoma)
firocoxib/previcox/equioxx
selective COX-2 inhibitor (class: coxib); has anti-cancer effects
robenacoxib/onisor
selective COX-2 inhibitor (class: coxib); approved for use in cats
meloxicam
selective COX-2 inhibitor (oxicam group); anti-cancer effects, approved for dogs, cats, large animal; warning of repeated use in cats can lead to acute renal failure and death
piroxicam
selective COX-2 inhibitor (oxicam group); for bladder transitional cell carcinoma & other cancers; not considered safe for routine use
banamine
non-specific COX inhibitor (class: flunixin meglumine); analgesic, antipyretic, anti-inflammatory; for musculoskeletal pain, colic, fever, and inflammation
flunixamine
non-specific COX inhibitor (class: flunixin meglumine); analgesic, antipyretic, anti-inflammatory; for musculoskeletal pain, colic, fever, and inflammation
dicolfenac sodium
non-specific COX inhibitor with possible lipooxygenase inhibition; for topical ophthalmic inflammation
tolfenamic acid
NSAID for pain and inflammation; approved for dogs and cats in Canada and Europe
grapiprant
PGE2 receptor antagonist at EP4 receptors; FDA approved for pain and inflammation from osteoarthritis in dogs; no approved use in cats
dimethyl sulfoxide (DMSO)
NSAID that blocks prostaglandin synthesis and traps free radical hydroxide; topical use for swelling (common ear med) or IV in equines
fuzapladib/panoquell-CA 1
leukocyte function antigen-1 inhibitor (prevents leukocyte adhesion to vascular endothelium and migration); approved for canine pancreatitis; IV SID 3x days
steroid medications
prednisone, prednisolone, dexamethasone, temaril P, hydrocortisone, methylprednisolone sodium succinate (SOLU), methylprednisolone acetate (depo), betamethasone, triamcinolone, fluticasone, budesonide
antihistamine H1 receptor antagonists
chlorpheniramine, diphenhydramine/benadryl, trimeprazine/temaril P, loratadine/claritin, cetirizine/zyrtec
antihistamine H2 receptor antagonists
famotidine/pepcid, ranitidine, cimetidine
immunomodulation
adjustment of immune response to a desired level
immunostimulation
stimulation of the immune system
immunosuppression
suppression of the immune system
induction of immunologic tolerance
decreasing immune response through small amounts of exposure, promoting development of tolerance
cyclosporine
immunosuppressant; suppresses t-cells by blocking calcineurin; NAMES: atomic, neural, gengraf, optimmune, sandimmune
tacrolimus
immunosuppressant; calcenurin inhbitor, blocks t-cell activation; topical for lupus, perianal fistula, KCS
oclacitinib
immunomodulator for atopic dermatitis and pruitis; blocks Janus Kinase enzyme (JAK), mostly JAK 1, causing Il-31 inhibition; cannot be given to young dogs
lokivetmab/cytopoint
monoclonal antibody that binds to nerve IL-31 receptors which blocks Il-31 from binding to its site
bedinvetmab/libela - canine
monoclonal antibody that blocks nerve growth factor, promotes neurogenic inflammation; avoid in pregnant or lactating dogs
frunevetmab/solensia - feline
monoclonal antibody that blocks nerve growth factor, limits release of proinflammatory mediators and lowers neurogenic inflammation
propionibacterium acnes injection
non-specific immunostimulant that induces macrophage activation and lymphokine production, increases natural killer cell activity, enhances cell-mediated immunity
staphylococcus aureus phage lysate (SPL)
immunostimulant that enhances cell-mediated immunity, increases macrophage activity, and stimulates TNF, IL-31, IL-Gamma, & Gamma-interferon production
canine parvovirus monoclonal antibody (CPMA)
monoclonal antibody for canine parvovirus, neutralizes virus before it enters the cell
filgrastim
recombinant human granulocyte colony-stimulating factor that stimulates bone marrow to produce WBCs